Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT

Donal P McLornan; Richard Szydlo; Marie Robin; Anja van Biezen; Linda Koster; Henrik J P Blok; Maria T Van Lint; Jürgen Finke; Antonin Vitek; Kristina Carlson; Laimonas Griskevicius; Ernst Holler; Maija Itälä-Remes; Michel Schaap; Gerard Socié; Jacques-Olivier Bay; Yves Beguin; Benedetto Bruno; Jan J Cornelissen; Tobias Gedde-Dahl; Per Ljungman; Marie T Rubio; Ibrahim Yakoub-Agha; Evgeny Klyuchnikov; Eduardo Olavarria; Yves Chalandon; Nicolaus Kröger

doi:10.1111/bjh.15407

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT

Br J Haematol. 2018 Aug;182(3):418-422. doi: 10.1111/bjh.15407. Epub 2018 May 29.

Authors

Donal P McLornan¹, Richard Szydlo², Marie Robin³, Anja van Biezen⁴, Linda Koster⁴, Henrik J P Blok⁴, Maria T Van Lint⁵, Jürgen Finke⁶, Antonin Vitek⁷, Kristina Carlson⁸, Laimonas Griskevicius⁹, Ernst Holler¹⁰, Maija Itälä-Remes¹¹, Michel Schaap¹², Gerard Socié³, Jacques-Olivier Bay¹³, Yves Beguin¹⁴, Benedetto Bruno¹⁵, Jan J Cornelissen¹⁶, Tobias Gedde-Dahl¹⁷, Per Ljungman¹⁸, Marie T Rubio¹⁹, Ibrahim Yakoub-Agha²⁰, Evgeny Klyuchnikov²¹, Eduardo Olavarria², Yves Chalandon²², Nicolaus Kröger²¹

Affiliations

¹ Comprehensive Cancer Centre, Division of Haematology, King's College, London.
² Hammersmith Hospital NHS Foundation Trust, London, United Kingdom.
³ Service d'Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.
⁴ EBMT Data Office, University Medical Centre, Leiden, the Netherlands.
⁵ Ospedale San Martino, Genova, Italy.
⁶ University of Freiburg, Freiburg, Germany.
⁷ Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
⁸ University Hospital Uppsala, Uppsala, Sweden.
⁹ Haematology, Oncology& Transfusion Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
¹⁰ Department of Haematology and Oncology, University of Regensburg, Regensburg, Germany.
¹¹ Stem Cell Transplant Unit, Turku University Hospital, Turku, Finland.
¹² Department of Haematology, Radboud University Medical Centre, Nijmegen, the Netherlands.
¹³ Service d'hématologie clinique Adulte et pédiatrie, CHU ESTAING, Clermont, France.
¹⁴ Department of Haematology, University of Liege, Liege, Belgium.
¹⁵ A.O.U Citta della Salute e della Scienza di Torino, S.S.C.V.D Trapianto di Cellule Staminali, Torino, Italy.
¹⁶ Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.
¹⁷ Clinic for Cancer, Surgery and Transplantation, Oslo University Hospital, Rikshospitalet, Norway.
¹⁸ Department of Haematology, Karolinska University Hospital, Stockholm, Sweden.
¹⁹ Department of Haematology, Hopital d`Enfants, Nancy, France.
²⁰ CHU de Lille, LIRIC, INSERM U995, Universite de Lille, Lille, France.
²¹ University Hospital Eppendorf, Hamburg, Germany.
²² Division of Haematology, Geneva University Hospitals, Geneva, Switzerland.

PMID: 29808926
DOI: 10.1111/bjh.15407

Abstract

Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.

Keywords: JAK inhibitors; allogeneic stem cell transplant; fibrosis; mylelofibrosis; relapse.

MeSH terms

Adult
Disease Management
Drug Therapy
Female
Hematopoietic Stem Cell Transplantation / methods*
Humans
Lymphocyte Transfusion
Male
Middle Aged
Primary Myelofibrosis / mortality
Primary Myelofibrosis / therapy*
Recurrence
Retrospective Studies
Survival Analysis
Transplantation, Homologous
Treatment Outcome